Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MEDI9197 |
Synonyms | |
Therapy Description |
MEDI9197 (telratolimod) acts an an agonist for the TLR7 and TLR8, potentially resulting in increased anti-tumor immune response (J Clin Oncol 34, 2016 (suppl; abstr TPS3095), PMID: 31511088). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MEDI9197 | MEDI-9197|MEDI 9197|Telratolimod|3M-052|3M 052 | TLR7 Agonist 12 TLR8 Agonist 9 | MEDI9197 (telratolimod) acts an an agonist for the TLR7 and TLR8, potentially resulting in increased anti-tumor immune response (J Clin Oncol 34, 2016 (suppl; abstr TPS3095), PMID: 31511088). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02556463 | Phase I | MEDI9197 Durvalumab + MEDI9197 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors | Terminated | USA | FRA | CAN | 0 |